Because high expression of IL-1β in macrophages in the intestine can significantly promote chronic inflammation and aggravate the symptoms of hyperglycemia, we concluded that administration of BD3526 metabolites significantly inhibits the expression of IL-1β in macrophages in the intestine (Ehses et al., 2007; Boni-Schnetzler et al., 2008; Eguchi et al., 2012; Jourdan et al., 2013). The gene discussed is IL1B; the disease is Hyperglycemia.